Molecular MRD is strongly prognostic in patients with <i>NPM1</i>-mutated AML receiving venetoclax-based nonintensive therapyJad Othman, Richard Dillon, Michael J. Austin et al.|Blood|2023Cited by 65
Real-world outcomes of newly diagnosed AML treated with venetoclax and azacitidine or low-dose cytarabine in the UK NHSJad Othman, Richard Dillon, Ho Pui Jeff Lam et al.|Blood Neoplasia|2024Cited by 36
Stearoyl-CoA desaturase inhibition is toxic to acute myeloid leukemia displaying high levels of the de novo fatty acid biosynthesis and desaturationVilma Dembitz, Paolo Gallipoli, Hannah Lawson et al.|Leukemia|2024Cited by 21